Fig. 5From: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)Waterfall plots showing the percent change from baseline in number of MHDs of Month 1 to 6 by baseline number of migraine headache daysBack to article page